Eisai Pharmaceuticals Single Person LLC
Basic information
- Head office
- 4-6-10 Koishikawa, Bunkyo-ku, Tokyo 112-8088, Japan
- Chief executive
- Haruo Naito
- Capital
- 44,986 JPY
- Employees (non-consolidated)
- 2,998 people
- Employees (consolidated)
- 10,917 people
- Start date
- 1941-12-06
- End date
Websites
Business
Related companies
| Company name | Group | Parent | Subsidiary | Customer | Supplier | Alliance | Bank | Shareholder |
|---|---|---|---|---|---|---|---|---|
|
|
||||||||
|
|
||||||||
|
|
||||||||
|
|
||||||||
|
|
||||||||
|
|
||||||||
|
|
||||||||
|
|
||||||||
|
|
||||||||
|
|
||||||||
|
|
||||||||
|
|
||||||||
|
|
||||||||
|
|
||||||||
|
|
||||||||
|
|
||||||||
|
|
||||||||
|
|
||||||||
|
|
||||||||
|
|
||||||||
|
|
||||||||
| Bogor Factory | ||||||||
| Eisai AB | ||||||||
| Eisai China Inc. | ||||||||
| Eisai Farmacêutica, Unipessoal Lda. | ||||||||
|
|
||||||||
| Eisai SA/NV | ||||||||
| Suzhou Factory | ||||||||
| Unlimit Health Limited |
Network
History
Eisai's founder, Toyoji Naito, is born on August 15 in Ito, a village in Fukui, central Japan. He is the sixth child and third son of Kikuji Naito and his wife, Fuji.![]()
Toyoji is employed at Winkel Shokai in nearby Kobe, a port city in Hyogo. Meanwhile, he takes night courses in foreign languages and bookkeeping.![]()
After completing military service, Toyoji begins working in imported drugs at Thompson Trading Co., Ltd. in Kobe.![]()
Toyoji moves to Tokyo and begins working at Tanabe Motosaburo Store Co., Ltd. (now part of the Mitsubishi Tanabe Pharma Corporation).![]()
Toyoji is involved in Tanabe Motosaburo Store Co., Ltd.'s development of aromatic castor oil : Castalol : and analgesic cream : Salomethyl : .![]()
The Great Kanto Earthquake strikes. Tanabe Motosaburo Store Co., Ltd. falls on hard times, including when its main store in Tokyo burns down in the aftermath of the quake.![]()
Tanabe Motosaburo Store Co., Ltd. acquires exclusive rights to market Japan's first anti-hypertensive drug, : Animasa : . A Japanese word Toyoji coins for 'high blood pressure' in his : Animasa : ad campaign enters the Japanese lexicon and remains a general medical term today.![]()
A : Salomethyl : newspaper ad created by Toyoji wins Best Advertisement Award in the first award ceremony of Japan's Society for the Promotion of Newspaper Advertising. Tanabe Motosaburo Store Co., Ltd. launches vitamin A product : Haliva : (halibut liver oil tablets).![]()
Sakuragaoka Laboratory Co., Ltd. launches vitamin E product : Juvela : through Tanabe Motosaburo Store Co., Ltd. Its chocolate-brown coating, 'hard outside, soft inside' pellets and stylish packaging garners much attention at the time. Juvela : becomes the laboratory's first success. Sakuragaoka Laboratory Co., Ltd. launches : Sampon : , Japan's first sanitary tampon, through Tanabe Motosaburo Store Co., Ltd.![]()
Nihon Eisai Co., Ltd., Eisai Co., Ltd.'s immediate predecessor, is established in Saitama, eastern Japan.![]()
Sakuragaoka Laboratory Co., Ltd. and Nihon Eisai Co., Ltd. merge under the name Nihon Eisai Co., Ltd.![]()
Nihon Eisai Co., Ltd.'s contraceptive suppository : Sampoon : , researched and developed during Japan's postwar baby boom, receives official approval from the Japanese government.![]()
Nihon Eisai Co., Ltd. launches high-dosage vitamin B1 and B2 product : Chocola BB Tablets : in Japan.![]()
Eisai opens its Taipei Office (now part of Eisai Taiwan Inc.), the company's first overseas branch, in Taiwan.![]()
Gastrointestinal remedies : Saclon : and : Saclon Tablets : , recognizable for their distinct green hue even today, are launched in Japan.![]()
Toyoji Naito receives the Japan Marketing Award, which recognizes people who have made a significant contribution to marketing and advertising in Japan.![]()
A three-tier representative director system is introduced: Chairman Toyoji Naito, President Yuji Naito, and Executive Vice President Tatsuo Naito.![]()
PT Eisai Indonesia is established as a pharmaceutical manufacturing and sales subsidiary in Indonesia.![]()
Toyoji Naito resigns as representative director and chairman to assume director and honorary chairman roles.![]()
Toyoji opens the Naito Museum of Pharmaceutical Science and Industry, Japan's first pharmaceutical museum, in Gifu.![]()
Hi-Eisai Pharmaceutical Inc. is established as a pharmaceutical sales subsidiary in the Philippines.![]()
Eisai Asia Regional Services Pte. Ltd. is established as a sales support and management services subsidiary in Singapore.![]()
Eisai U.S.A. Inc. is established as a chemical and pharmaceutical machinery sales subsidiary in California, the United States.![]()
Eisai Chemical Co., Ltd. (now Eisai's Kashima Plant) is established in Ibaraki to manufacture active pharmaceutical ingredients (APIs).![]()
Eisai has supported of the Health and Medical Care Contributions Awards, which are presented to healthcare professionals who have contributed significantly to improving access to healthcare in difficult-to-reach areas from 1987 to 2015.![]()
Eisai Research Institute of Boston, Inc. (now the Boston Research Institute) is established as a discovery research subsidiary in Massachusetts, the United States.![]()
President Yuji Naito steps down from office and assumes the role of chairman; Vice President Haruo Naito is appointed president of Eisai.![]()
Eisai America, Inc. is established as a clinical research subsidiary in New Jersey, the United States.![]()
Eisai Machinery GmbH is established as a pharmaceutical machinery sales subsidiary in Cologne, former West Germany.![]()
Eisai (Thailand) Marketing Co., Ltd. is established as a pharmaceutical sales subsidiary in Bangkok, Thailand.![]()
Eisai London Research Laboratories, Ltd. is established as a discovery research subsidiary attached to University College London in the United Kingdom.![]()
Shenyang Eisai Pharmaceutical Co., Ltd. is established as a Chinese–foreign contractual joint venture in pharmaceutical manufacturing and sales in Shenyang, China.![]()
Eisai Corporation of North America is established as a holding company in New Jersey, the United States.![]()
Eisai London Research Laboratories, Ltd. is completed in the United Kingdom to form an Eisai Group multipolar R&D network spanning Japan, America and Europe.![]()
Eisai London Research Laboratories opening ceremony in 1993 attended by the United Kingdom's Princess Royal, Princess Anne.![]()
Eisai Suzhou Pharmaceutical Co., Ltd. is established as a pharmaceutical manufacturing and sales subsidiary in Jiangsu, China.![]()
KAN Research Institute, Inc. (now Kobe Research Laboratories, in Hyogo) is established as a life science exploratory research subsidiary in Osaka, Japan.![]()
Eisai Inc. North Carolina Plant is established as a pharmaceutical manufacturing and formulation R&D facility at Research Triangle Park in North Carolina, the United States.![]()
Eisai Farmacéutica S.A. is established as a pharmaceutical sales and marketing subsidiary in Madrid, Spain.![]()
Eisai Medical Research Inc. is established as a clinical research subsidiary in New Jersey, the United States.![]()
Eisai Europe Ltd. is established as a European regional headquarters (holding company) in London, the United Kingdom.![]()
Eisai Pharmaceuticals India Pvt. Ltd. is established as a pharmaceutical sales subsidiary in Mumbai, India.![]()
Eisai Clinical Research Singapore Pte. Ltd. is established as a clinical research subsidiary in Singapore.![]()
EF-Eisai Farmacêutica, Unipessoal Lda. is established as a pharmaceutical sales subsidiary in Lisbon, Portugal.![]()
Eisai Manufacturing Ltd. is established as a pharmaceutical manufacturing subsidiary in Hertfordshire, the United Kingdom.![]()
Eisai Pharmatechnology & Manufacturing Pvt. Ltd. is established as an API/formulation manufacturing and R&D subsidiary in Vizag, India.![]()
Eisai Machinery Shanghai Inc. is established as a subsidiary in Shanghai, China to provide marketing support and maintenance services for pharmaceutical machinery.![]()
The European Knowledge Centre (now EMEA Knowledge Centre) opens as a European strategic base in Hertfordshire, the United Kingdom.![]()
The Eisai Product Creation Systems organizational structure is introduced Group-wide to reflect a new focus on patient-oriented R&D.![]()
Haruo Naito is appointed as president of the International Federation of Pharmaceutical Manufacturers & Associations.![]()
The Eisai Knowledge Centre, India opens as a manufacturing and process research base in Vizag, India.![]()
The Koishikawa Knowledge Center opens in Tokyo and receives the 24th Nikkei New Office Promotion Award.![]()
Production headquarters transforms to a global “Eisai Demand Chain Systems” structure to reflect a new “demand-driven” customer satisfaction focus in drug manufacturing.![]()
Eisai (Suzhou) Trading Co., Ltd. is established as a pharmaceutical trading subsidiary in Jiangsu, China.![]()
Eisai signs a statement with the World Health Organization (WHO) to supply a primary lymphatic filariasis medicine free of charge.![]()
Eisai Laboratorios S. de R.L. de C.V. is established as a pharmaceutical sales subsidiary in Mexico City, Mexico.![]()
Eisai signs the London Declaration, which is committed to the elimination of ten neglected tropical diseases by 2020.![]()
Haruo Naito is appointed as president of the Federation of Pharmaceutical Manufacturers' Associations of Japan (FPMAJ).![]()
Limited Liability Company Eisai is established as a pharmaceutical sales subsidiary in Moscow, Russia.![]()
Eisai co-establishes the Global Health Innovative Technology Fund (GHIT Fund), Japan's first public–private partnership to advance development of new health technologies for the developing world.![]()
Eisai initiates free of charge provision of diethylcarbamine tablets produced at its Vizag plant in India to WHO for use in the treatment of lymphatic filariasis.![]()
Eisai completes acquisition of Chinese generic pharmaceutical company Liaoning Tianyi Biological Pharmaceutical Co., Ltd. (new trading name: Eisai (Liaoning) Pharmaceutical Co., Ltd.)![]()
Collaboration agreement with Biogen to develop and commercialize investigational Alzheimer's disease treatments including aducanumab expanded.![]()
Eisai agrees upon a strategic collaboration for : Lenvima : with Merck & Co., Inc., Kenilworth, N.J., U.S.A.![]()
Eisai Center for Genetics Guided Dementia Discovery (G2D2) in Massachusetts, U.S., commences full-scale operation.![]()
NouKNOW (pronounced “NOH-NOH”), a new tool for self-assessment of brain performance (brain health) is launched in Japan.![]()
Eisai Vietnam Co., Ltd. is established as a pharmaceutical sales subsidiary in Ho Chi Minh City, Vietnam.![]()
Alzheimer’s disease treatment ADUHELM is granted accelerated approval and launched in the United States.![]()
Eisai enters into a global strategic collaboration agreement with Bristol-Myers Squibb Company for MORAb-202.![]()
Eisai Pharmaceuticals Africa (Pty) Ltd is established as a pharmaceutical sales subsidiary in Johannesburg, South Africa.![]()
Eisai signs the public private partnership “Kigali Declaration” for eliminating neglected tropical diseases.![]()
News
There is no news.